Suhas Ramesh

Dr. Suhas Ramesh

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2023 in Antibiotics
Verified
Journal Article
Open access
PDF file
RGRohith Gattu
Rohith Gattu
SRSanjay S Ramesh
Sanjay S Ramesh
SNSiddaram Nadigar
Siddaram Nadigar
CDChanne Gowda D
Channe Gowda D
SRSuhas Ramesh
Suhas Ramesh
Peptide-based drugs are gaining significant momentum in the modern drug discovery, which is witnessed by the approval of new drugs by the FDA in recent years. On the other hand, small molecules-based drugs are an integral part of drug development since the past several decades. Peptide-containing drugs are placed between small molecules and the biologics. Both the peptides as well as the small molecules (mainly heterocycles) pose several drawbacks as therapeutics despite their success in curing many diseases. This gap may be bridged by utilising the so called ‘conjugation chemistry’, in which both the partners are linked to one another through a stable chemical bond, and the resulting conjugates are found to possess attracting benefits, thus eliminating the stigma associated with the individual partners. Over the past decades, the field of molecular hybridisation has emerged to afford us new and efficient molecular architectures that have shown high promise in medicinal chemistry. Taking advantage of this and also considering our experience in this field, we present herein a review concerning the molecules obtained by the conjugation of peptides (amino acids) to small molecules (heterocycles as well as bioactive compounds). More than 125 examples of the conjugates citing nearly 100 references published during the period 2000 to 2022 having therapeutic applications in curing infectious diseases have been covered.

18 January 2024 in Microbial Pathogenesis
Verified
Journal Article
Closed access
RGRohith Gattu
Rohith Gattu
SRSanjay S. Ramesh
Sanjay S. Ramesh
SRSuhas Ramesh
Suhas Ramesh

22 June 2022 in European Journal of Medicinal Chemistry Reports
Verified
Journal Article
Open access
SRSuhas Ramesh
Suhas Ramesh

15 January 2024 in Asian Journal of Organic Chemistry
Verified
Journal Article
Closed access
SRSanjay S. Ramesh
Sanjay S. Ramesh
RGRohith Gattu
Rohith Gattu
SRSuhas Ramesh
Suhas Ramesh

1 February 2022 in Results in Surfaces and Interfaces
Verified
Journal Article
Open access
SRSrilatha Rao
Srilatha Rao
SRSuhas Ramesh
Suhas Ramesh
MMMahadevaswamy M.
Mahadevaswamy M.
PCPradeep Kumar C.B.
Pradeep Kumar C.B.
Gururaj Kudur JayaprakashGururaj Kudur Jayaprakash
Gururaj Kudur Jayaprakash
SKSandeep Kumar
Sandeep Kumar

12 September 2024 in Future Medicinal Chemistry
Verified
Journal Article
Closed access
SNSiddaram Nadigar
Siddaram Nadigar
RGRohith Gattu
Rohith Gattu
SRSanjay Ramesh
Sanjay Ramesh
RDRekha N Dharmappa
Rekha N Dharmappa
VNVijendra Kumar Nanjundaswamy
Vijendra Kumar Nanjundaswamy
SRSuhas Ramesh
Suhas Ramesh
Aim: Angiogenesis is the hallmark of cancer progression driven by VEGF/VEGFR-2 signalling pathway, inhibition of which could be a solution to tackle the progression of tumour cells and thus arresting their growth.Materials & methods: A novel class of pyrazoles was synthesized using arginine and dibromo ketones. Antiangiogenic activity was performed by in vivo yolk sac method. Antioxidant activity was evaluated by hydroxyl and superoxide radical scavenging assays. Docking studies were performed to determine the pyrazoles' binding potential with VEGFR-2 receptor and VEGF tyrosine kinase. ADMET properties were calculated using SwissADME and admetSAR for drug-likeness.Results: Compounds 5a-e showed significant antiangiogenic effects. Compound 5f exhibited effective hydroxyl and superoxide radical scavenging activities. Docking results confirmed the potential binding efficiency with VEGFR-2 receptor over VEGF tyrosine kinase, thus, functioning as competitive-inhibitors. ADMET studies revealed that the compounds possess favourable drug-like qualities.Conclusion: This study presents a novel class of pyrazoles as promising antioxidant and antiangiogenic agents with favourable drug-likeness properties.